PathWhiz

PathWhiz ID	Pathway	Meta Data
PW127360 View Pathway	disease Triosephosphate Isomerase Deficiency Homo sapiens Triosephosphate isomerase deficiency is a genetic disorder caused by a mutation in the TPI1 gene. The mutation of this gene causes the production of enzymes that are unstable or enzymes that have reduced activity. This means that cells have reduced energy supplies as glycolysis is compromised. This disorder causes anemia, movement problems and muscle weakness. As a result of the lack of red blood cells to carry oxygen through the body, patients may experience fatigue and shortness of breath. Movement problems appear in early infancy, typically before the age of 2 in patients with this disorder. Treatment includes blood transfusions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: December 16, 2022 at 11:07 Last Updated: December 16, 2022 at 11:07
PW122107 View Pathway	disease Triosephosphate Isomerase Deficiency Rattus norvegicus Triosephosphate isomerase deficiency is a genetic disorder caused by a mutation in the TPI1 gene. The mutation of this gene causes the production of enzymes that are unstable or enzymes that have reduced activity. This means that cells have reduced energy supplies as glycolysis is compromised. This disorder causes anemia, movement problems and muscle weakness. As a result of the lack of red blood cells to carry oxygen through the body, patients may experience fatigue and shortness of breath. Movement problems appear in early infancy, typically before the age of 2 in patients with this disorder. Treatment includes blood transfusions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ana Marcu Created On: September 10, 2018 at 15:52 Last Updated: September 10, 2018 at 15:52
PW121883 View Pathway	disease Triosephosphate Isomerase Deficiency Mus musculus Triosephosphate isomerase deficiency is a genetic disorder caused by a mutation in the TPI1 gene. The mutation of this gene causes the production of enzymes that are unstable or enzymes that have reduced activity. This means that cells have reduced energy supplies as glycolysis is compromised. This disorder causes anemia, movement problems and muscle weakness. As a result of the lack of red blood cells to carry oxygen through the body, patients may experience fatigue and shortness of breath. Movement problems appear in early infancy, typically before the age of 2 in patients with this disorder. Treatment includes blood transfusions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ana Marcu Created On: September 10, 2018 at 15:50 Last Updated: September 10, 2018 at 15:50
PW000539 View Pathway	disease Triosephosphate Isomerase Deficiency Homo sapiens Triosephosphate isomerase deficiency is a genetic disorder caused by a mutation in the TPI1 gene. The mutation of this gene causes the production of enzymes that are unstable or enzymes that have reduced activity. This means that cells have reduced energy supplies as glycolysis is compromised. This disorder causes anemia, movement problems and muscle weakness. As a result of the lack of red blood cells to carry oxygen through the body, patients may experience fatigue and shortness of breath. Movement problems appear in early infancy, typically before the age of 2 in patients with this disorder. Treatment includes blood transfusions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 29, 2013 at 10:39 Last Updated: August 29, 2013 at 10:39
PW058512 View Pathway	drug action Tripelennamine H1-Antihistamine Action Homo sapiens Tripelennamine is a first-generation ethylenediamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: September 15, 2017 at 15:28 Last Updated: September 15, 2017 at 15:28
PW058506 View Pathway	drug action Triprolidine H1-Antihistamine Action Homo sapiens Triprolidine is a first-generation alkylamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: September 15, 2017 at 13:37 Last Updated: September 15, 2017 at 13:37
PW000680 View Pathway	drug action Trisalicylate-Choline Action Pathway Homo sapiens Trisalicylate-Choline (also named Choline Magnesium Trisalicylate) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to treat pain and fever. Trisalicylate-Choline can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of trisalicylate-choline. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: April 26, 2014 at 12:51 Last Updated: April 26, 2014 at 12:51
PW122501 View Pathway	metabolic Triterpenoid Biosynthesis Arabidopsis thaliana Triterpenoids have 30 carbons and six isoprene units. They are derived from (S)-2,3-epoxysqualene. They may contain rings or be acyclic, depending on the bonds formed by the loss of the diphosphate group. First, the terpenoid backbone is synthesized, producing farnesyl pyrophosphate. Two molecules of farnesyl pyrophosphate then join together to form presqualene diphosphate, catalyzed by squalene synthase 1. Then, the same enzyme removes the pyrophosphate group and replaces it with a hydrogen ion, forming squalene. Squalene then undergoes oxidation of one of its bonds via squlene monooxygenase 1, to form (S)-2,3-epoxysqualene. This may then proceed to the steroid biosynthesis pathway or may react with an isomerase or lyase to form a chair-chair-chair-boat triterpenoid. Similarly, squalene may interact with an isomerase or lyase to form a chair-chair-chair-chair triterpenoid. After the backbone is complete, (S)-2,3-epoxysqualene can interact with many enzymes in order to form the triterpenoids. It can interact with camelliol C synthase to form camelliol C, thalianol synthase to form thalianol, baruol synthase to form baruol, tirucalladienol synthase to form tirucalla-7,24-dien-3-beta-ol, amyrun synthase LUP2 to form lupeol, alpha- and beta-amyrin synthases to form alpha- and beta-amyrin respectively. It can also interact with lupan-3beta,20-diol synthase to add a water molecule to form lupan-3beta,20-diol, alpha- and beta-seco-amyrin synthases to form alpha- and beta-seco-amyrin respectively, marneral synthase to form marneral, and finally arabidiol synthase to add a water molecule and form arabidiol. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: May 08, 2019 at 15:20 Last Updated: May 08, 2019 at 15:20
PW126958 View Pathway	metabolic triterpenoid biosynthesis Camellia nitidissima BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ping Created On: May 25, 2022 at 18:41 Last Updated: May 25, 2022 at 18:41
PW063854 View Pathway	drug action Tritoqualine H1-Antihistamine Action Homo sapiens Tritoqualine is an H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: September 24, 2017 at 23:27 Last Updated: September 24, 2017 at 23:27